Hemostemix Inc. (CVE:HEM – Get Free Report) shares were down 8.3% on Thursday . The stock traded as low as C$0.11 and last traded at C$0.11. Approximately 240,655 shares changed hands during trading, an increase of 150% from the average daily volume of 96,162 shares. The stock had previously closed at C$0.12.
Hemostemix Trading Down 8.3 %
The company has a market capitalization of C$9.58 million, a price-to-earnings ratio of -5.50 and a beta of 0.20. The firm has a 50-day simple moving average of C$0.08 and a two-hundred day simple moving average of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- How to Calculate Inflation Rate
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
